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Abstract 
A previous in vitro study revealed that Wilms’s tumor 1 (WT-1) transcripts were detectable in 
7 of 9 melanoma cell lines, but not in any of 5-normal melanocyte strains tested. Our current 
study assessed the expression levels of WT-1 protein in clinical samples, to determine 
whether the expression levels of the WT-1 protein may be used as a novel marker to assist 
differential diagnosis. Paraffin-embedded tissue sections from 15 cases of malignant mela-
nomas and 25 cases of benign nevi were subjected to immunohistochemistry with a mo-
noclonal antibody against the human WT-1 protein. The expression levels of WT-1 protein 
among normal, benign, and malignant melanocytes were semi-quantitatively assessed. Strong 
and uniform WT-1 immunoreactivities were seen in all or nearly all tumor cells in both the 
junctional and dermal components of all malignant melanomas, and also in a vast majority of 
the tumor cells of Spitz’s (n = 8), recurrent (n = 2), and junction (n = 2) nevi. Distinct WT-1 
immunoreactivities were also seen in some isolated individual tumor cells or tumor cell 
clusters in the junctional component of compound nevus (9) and in intradermal nevus (2). It is 
interesting to note that some isolated normal appearing melanocytes or cell clusters, and all 
morphologically distinct endothelial cells were strongly positive to WT-1. However, all tumor 
cells within the dermal component of compound (n = 9) or deep penetrating nevi (n = 1), or 
capsular nevus inclusion of lymph node (1) were devoid of WT-1 expression. Our findings 
suggest that the expression level of the WT-1 protein has no significant value in distinguishing 
between Spitz’s nevi and malignant melanoma, but it may be a useful marker in differentiating 
between benign and malignant melanocytes within the dermal component. Our findings also 
suggest that aberrant WT-1 expression may have oncogenic properties that promote the 
initiation and progression of melanocytic lesions.  
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Introduction 
The incidence and mortality of melanoma have 
steeply increased in the last century mainly due to the 
earlier occurrence of primary lesions in young people 
and late detection of biologically aggressive nodular 
melanomas [1-5]. Clinically, there are a variety of 
melanocytic lesions, including atypical Spitz’s nevus, 
pigmented spindle cell nevus, deep penetrating ne-
vus, and atypical combined nevus, that often mor-
phologically and immunohistochemically mimic me-
lanoma [6-11]. Therefore, there is an urgent need to Journal of Cancer 2010, 1 
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identify novel biochemical and/or molecular markers 
that are melanoma-specific, to assist clinical differen-
tiation, early detection, and intervention of melano-
ma.  
A previous study revealed that Wilms’ tumor 1 
(WT-1) gene was differentially expressed in cultured 
human normal and malignant melanocytes [12]. With 
PCR analysis, WT-1 transcripts were detected in 7 of 9 
melanoma cell lines but not in any of 5-normal mela-
nocyte strains. With Northern blot analysis, 
steady-state WT-1 mRNA levels were seen in 2 of 4 
melanoma cell lines but not in any of the normal me-
lanocytes [12]. Together, these findings suggest that 
the products of the WT-1 gene may be exclusively or 
preferentially expressed in malignant melanocytes. 
Based on the above findings, our current study 
attempts to assess the expression status of WT-1 pro-
tein in normal, benign, and malignant melanocytes of 
clinical samples, to determine whether the expression 
levels of the WT-1 protein  may be used as a novel 
marker to assist differential diagnosis among different 
melanocytic lesions in clinical samples.  
Materials and Methods 
Formalin-fixed, paraffin-embedded tissue blocks 
from 15 patients with malignant melanomas, and 25 
with benign nevi (including 9 compound nevi, 8 
Spitz’s nevi, 4 junctional nevi, 2 intradermnal nevi, 1 
deep penetrating nevus and 1 capsular nevus inclu-
sion in a lymph node), were retrieved from the files of 
Armed Forces Institute of Pathology. Consecutive 
sections at 4-5 μm thickness were cut, placed on posi-
tively charged slides, and subjected to morphological 
and immunohistochemical assessment. Immunohis-
tochemical staining was conducted using our pub-
lished protocol [13]. Briefly, sections were incubated 
at 60-70 0C for 1 hour, deparaffinized with xylene, and 
washed with ethanol and water. Deparaffinized sec-
tions were incubated in 1X antigen retrieval solution 
(Biocare Medical, Foster City, CA) overnight at 60-70 
0C, washed in water and phosphate-buffered saline 
(PBS), treated with 3% hydrogen peroxide and normal 
serum, and incubated with a monoclonal anti-WT-1 
antibody (6f-H2; Cat #: CMC789; Cell Marque, Hot 
Springs, AR) in a dilution of 1:20 at room temperature 
for 3-4 hours. After incubation with the primary an-
tibody, sections were washed with PBS, and sequen-
tially incubated with the corresponding secondary 
antibody, avidin-biotin-peroxidase solution, and 
chromogen diaminobenzidine (Vector, Burlingame, 
CA). After the chromogen reaction, sections were 
counterstained with hematoxylin, washed in tap wa-
ter, dehydrated in ascending concentrations of etha-
nol, cleared in xylene, and mounted for evaluation. 
The expression status of WT-1 among these le-
sions was independently examined by two investiga-
tors. A given cell was considered WT-1 positive if 
distinct chromogen coloration was consistently seen 
in its cytoplasm or nucleus in at least two duplicates 
of the same immunostaining procedure. The intensity 
of WT-1 immunostaining was graded as diffusible (+), 
weak (++), moderate (+++), strong (++++), and very 
strong (+++++). The percentage of WT-1 positive cells 
was grade as 0 (negative), 1+ (<10%), 2+ (about 30%), 
3+ (about 50%), 4+ (about 75%), and 5+ (all or nearly 
all cells).  
To assess the specificity of the immunostaining, 
different controls were used, which included: (1) the 
substitution of the primary antibody with the normal 
serum, (2) the omission of the secondary antibody 
and, (3) serial dilutions of the primary antibody. All 
the immunostainings was repeated at least twice un-
der the same condition.  
Results 
 All negative controls were completely devoid of 
distinct WT-1 immunoreactivity. In sharp contrast, all 
or nearly all malignant melanocytes in both the junc-
tional and dermal component were strongly and un-
iformly positive for WT-1 (Fig 1a-1d). Similarly, a vast 
majority of the tumor cells of Spitz’s, as well as re-
current and junction nevi (Fig 1e-1h) were positive for 
WT-1. It is interesting to note that some isolated nor-
mal melanocytes or cell clusters were strongly posi-
tive to WT-1 (Fig 2a-2d). These WT-1 positive nor-
mal-appearing melanocyte clusters often displayed 
some malignancy-associated changes, including the 
loss of polarity, focal disruption of the basement 
membrane, and morphological resemblance to ma-
lignant melanocytes (Fig 2a-2d). It is also interesting 
to note that all morphologically distinct endothelial 
cells were strongly positive to WT-1 (Fig 2e-2f). Dis-
tinct WT-1 immunoreactivities were also seen in some 
isolated individual tumor cells or tumor cell clusters 
in the junctional component of compound nevus and 
in intradermal nevus, whereas all tumor cells within 
the dermal component of compound or deep pene-
trating nevi, or capsular nevus inclusion of lymph 
node were devoid of WT-1 expression (Fig 2g-h). The 
sub-cellular localization of WT-1 expression is pre-
dominantly in the cytoplasm, which is consistent with 
that of our previous study in human breast tissues 
[13]. The rough percentage of WT-1 positive cells and 
intensity of WT-1 immunostaining are listed in Table 
1.  
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Fig 1. WT-1 expression in melanoma and Spitz’s nevi. Paraffin-embedded tissue sections from patients with me-
lanocytic lesions were immunostained for WT-1 protein. Circles identify morphologically similar malignant and benign 
melanocytes with distinct WT-1 immunoreactivities. Note that all or nearly all the tumor cells of in situ and spreading 
melanomas (a-d) were strongly and uniformly positive for WT-1. Similar WT-1 immunostaining was also seen in all or nearly 
tumor cells in both the junctional and dermal components of Spitz’s nevi (e-h). a, c, e, and g: 100X. b, d, f, and h: a higher 
magnification (300X) of a, c, e, and g, respectively.  Journal of Cancer 2010, 1 
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Fig 2: WT-1 expression in normal appearing melanocytes and endothelial cells. Paraffin-embedded tissue sec-
tions from patients with melanocytic lesions were immunostained for WT-1 protein. Circles identify melanocyte clusters 
with WT-1 immunoreactivities in normal appearing tissues (a-d) and without WT-1 immunoreactivities in the dermal 
component of compound or deep penetrating nevi. Arrows identify small blood vessels (f) and isolated melanotyes (h) with 
WT-1 immunoreactivities. a, c, e, and g: 100X. b, d, f, and h: a higher magnification (300X) of a, c, e, and g, respectively. 
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Table 1. Comparison of WT-1 Expression in different melanocytic lesions 
Melanocytic lesion types  Intensity and percentage of positive cells in 
junctional component  
Intensity and percentage of positive cells in 
dermal component 
Melanoma in situ (3)   +++++/+++++   NA 
Superficial spreading MM (2)   +++++/+++++   +++++/+++++ 
Nodular MM (8)   +++++/+++++   +++++/+++++ 
Metastatic MM (1)   NA   +++++/+++++ 
Desmoplastic MM (1)   NA   ++++/++++  
Spitz’s nevus (8)   +++++/++++   +++++/++++ 
Recurrent nevus (2)   +++++/++++   NA 
Junction nevus (2)   +++++/++++   NA 
Compound nevus (9)   +++++/+   0/0 
Deep penetrating nevus (1)   NA   0/0 
Intradermal nevus (2)   NA   +/+ 
Capsular nevus inclusion of  
lymph node (1) 
 N/A    0/0 
Intensity was graded as follows: 5+, strongest and 1+, weakest, and 0, no staining. Sensitivity was graded as follows: 4+, diffuse staining of 
all melanocytes, 3+, about 75% and 2+, about 50 % and 1+, less than 25%. NA-not applicable. 
 
Discussion 
The findings of our study appear to be in accor-
dance with the findings of WT-1 staining in tissue 
cultures, in which melanoma cells are positive and 
normal melanocytes are negative for WT-1 [12]. 
However, the WT-1 expression is demonstrated not 
only in malignant melanoma in situ, superficial 
spreading melanomas, nodular melanomas, and me-
tastatic melanomas, but also in Spitz’s nevi, junctional 
nevi, particularly in recurrent nevi, and upper dermal 
melanocytes of benign nevi. These findings would 
suggest that differentiating between melanomas and 
atypical Spitz’s nevus is not possible with WT-1 
staining. Our findings are consistent with those of a 
recent study [14]. However, the WT-1 staining can be 
used as an adjuvant tool for differentiation between 
benign and malignant melanocytes within the dermal 
component. No definite conclusion, however, could 
be made at present, as the sample size of this study is 
too small.   
It is interesting to note that a subset of isolated 
normal appearing melanocytes or melanocyte clusters 
are strongly positive for WT-1 (as those shown in Fig 
2a-2d). Compared to their adjacent counterparts, these 
WT-1 positive normal-appearing melanocyte clusters 
generally display some malignancy-associated 
changes, including increased cell density, loss of po-
larity, focal disruptions of the basement membrane, 
and morphological resemblance to malignant mela-
nocytes. It is also interesting to note that all or nearly 
all morphologically identifiable vascular structures 
show distinct WT-1 immunostaining (as those shown 
in Fig 2e-2f). The clinical significance of WT-1 expres-
sion in normal appearing melanosytes and endotheli-
al cells is unknown. However, based on the fact that 
the expression level of WT-1 appear to increase with 
the increasing degree of malignancy, it is reasonable 
to speculate that aberrant WT-1 expression may have 
oncogenic properties that promote the initiation and 
progression of melanocytic lesions, and that the nor-
mal appearing melanosytes with strong WT-1 expres-
sion may represent the direct precursor of malignant 
melanoma. More importantly, as WT-1 is uniformly 
and strongly expressed in all malignant melanocytes 
and endothelial cells, the development of specific 
agents to manipulate the expression of WT-1 may 
have significant therapeutic value in malignant me-
lanoma 
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